more_reports

Biotech to Fast Track Phase 3 Depression Trial

Research Report
  ()
Alto Neuroscience Inc. (ANRO:NYSE) intends to carry out this newly added study, supported by a recent financing, and the previously planned Phase 2b trial simultaneously, noted a William Blair report.
Tags: Biotechnology / Pharmaceuticals

2 Key Catalysts Ahead for Developer of Psych Drugs

Research Report
  ()
Alto Neuroscience Inc. (ANRO:NYSE) expects to release topline trial data in 2025 and commence a separate study in 2026, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Co. Speeds Up Development of New Drug for Depression

Research Report
  ()
Alto Neuroscience Inc. (ANRO:NYSE) plans Phases 2b and 3 trials of its asset, ALTO-207, in treatment-resistant depression, noted a Jefferies report.
Tags: Biotechnology / Pharmaceuticals

Price Target on Psychiatric Drug Biotech Boosted 200%

Research Report
  ()
Alto Neuroscience Inc. (ANRO:NYSE) completed a US$50 million equity raise and announced plans to accelerate development of its recently acquired asset in treatment-resistant depression, noted a Wedbush report.
Tags: Biotechnology / Pharmaceuticals

US Biopharma In-Licenses 3 New Assets

Research Report
  ()
Zenas BioPharma Inc.'s (ZBIO:NASDAQ) target price is increased 14% to reflect the Phase 3 investigative multiple sclerosis drug included in this recent deal, noted a Wedbush report.
Tags: Biotechnology / Pharmaceuticals

Chen's High-Grade Gold, Silver Plays for Q4

  ()
It has been quite a year for precious metals such as gold and silver, and Chen Lin's top stock picks for the quarter bear that out. Which companies have the most upside?
Tags: CopperBiotechnology / PharmaceuticalsGoldSilver

AI Cancer Discovery Shows Breakthrough in Brain-Targeting Treatment

  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) is set to unveil new preclinical data from its AI-driven ATR inhibitor program at a major international cancer conference in Boston. The findings highlight strong efficacy and blood-brain barrier permeability, a potential breakthrough for hard-to-treat tumors and brain metastases.
Tags: Healthcare ServicesBiotechnology / Pharmaceuticals

Cleantech Co. Advances Antimicrobial Wound Care Breakthrough

  ()
Cleantech innovation company BioLargo Inc. (BLGO:OTCQX) announced that subsidiary Clyra Medical Technologies is making significant strides. Read why one analyst says the technology is on "the cusp of commercialization."
Tags: Medical DevicesLife Sciences Tools & Diagnostics

Biopharma's New MASH Drug Has Two MOAs

Research Report
  ()
Altimmune Inc.'s (ALT:NASDAQ) pemvidutide achieves metabolic improvement and directs hepatic anti-fibrotic activity with singular dosing, noted an H.C. Wainwright & Co. report.
Tags: Biotechnology / Pharmaceuticals

Life Sciences Co. Reports Strong Survival Data

Research Report
  ()
OS Therapies Inc.'s (OSTX:NYSEAMERICAN) trial results are for its new immunotherapy in fully resected pulmonary metastatic osteosarcoma, noted a D. Boral Capital report.
Tags: Regenerative Medicine

Therapeutics Company Advances Gene Therapy Breakthrough

Research Report
  ()
In an updated research note on October 7, H.C. Wainwright & Co. analysts Mitchell Kapoor and Dr. Raghuram Selvaraju note significant risk reduction for Lexeo Therapeutics Inc. (LXEO:NASDAQ) as formal alignment with the FDA makes its new drug increasingly likely to gain approval.
Tags: Regenerative MedicineBiotechnology / Pharmaceuticals

Biotech Firm Uncovers Breakthrough Gene Therapy in New York

  ()
Lexeo Therapeutics Inc. (LXEO:NASDAQ) advanced its LX2006 program after new FDA feedback supported an accelerated approval path. Read how interim data showed strong cardiac and neurological improvements, prompting bullish analyst upgrades.
Tags: Healthcare Services

Pharma Announces Faster Approval Pathway for Neurodegenerative Disease

Research Report
  ()
Lexeo Therapeutics Inc. (LXEO:NASDAQ) announces a faster approval pathway for LX2006 in Friedreich's ataxia (FA). Find out why two analysts believe the company is emerging as a leader in developing transformative gene therapies for rare cardiac and neurodegenerative diseases.
Tags: Biotechnology / PharmaceuticalsRegenerative Medicine

Healthcare Tech Firm Finds Big U.S. Opportunity

  ()
Healthcare data firm OneMedNet Corporation (Nasdaq: ONMD) partners with Palantir Technologies Inc. (PLTR:NASDAQ) to analyze over 5 billion claims and 131 million exams, unlocking a possible massive U.S. breakthrough in AI-driven research.
Tags: Healthcare Services

New Drug for Duchenne Muscular Dystrophy Nears Potential Approval

Research Report
  ()
Capricor Therapeutics Inc. (CAPR:NASDAQ) could receive a PDUFA date for its cell therapy as early as spring 2026 if it follows the FDA-outlined path forward, noted an Alliance Global Partners report.
Tags: Biotechnology / Pharmaceuticals

Clean Tech Co.'s 'Forever Chemical' Solution Is a PFAS Breakthrough

  ()
Clean technology company BioLargo Inc. (BLGO:OTCQX) announced compelling new findings about its proprietary Aqueous Electrostatic Concentration (AEC) "forever chemicals" solution. Read to discover why one expert thinks the breakthrough is important to the company's future.
Tags: Alternative - CleantechMedical DevicesAlternative EnergyHealthcare ServicesBattery Metals

Expert Investing Ideas

Streetwise Reader Icon Streetwise Key Charts
Pharma Biotech & Life Sci

Get Our Streetwise Reports' Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

Biotech Secures FDA Alignment on Late-Stage Duchenne Therapy

  ()
Capricor Therapeutics Inc. (CAPR:NASDAQ) reached agreement with the FDA to include HOPE-3 trial data in its BLA for Deramiocel, its cell therapy for Duchenne muscular dystrophy. With topline results due in Q4, learn how the company is advancing one of the few late-stage programs in this high-need rare disease space.
Tags: Biotechnology / Pharmaceuticals

Biotech Battles FDA, Target Price Shows Potential 90% Gains

Research Report
  ()
Capricor Therapeutics Inc. (CAPR:NASDAQ) has recently been involved in a "tug-of-war with the FDA." Read on to see why one Roth analyst still rates this stock as a Buy.
Tags: Life Sciences Tools & Diagnostics

Pharma's Flu Drug Could Be Worth Billions, Analyst Says

Research Report
  ()
Cidara Therapeutics Inc. (CDTX:NASDAQ) shares the minutes from an important meeting with the FDA, and the overall feedback was encouraging. Find out what one analyst predicts that will mean for Phase III development.
Tags: Biotechnology / Pharmaceuticals

Biotech Discovers Breakthrough DMD Therapy Opportunity

Research Report
  ()
Capricor Therapeutics Inc. (CAPR:NASDAQ) recently announced a favorable regulatory update, according to a research note from Oppenheimer & Co Inc.
Tags: Biotechnology / Pharmaceuticals

Seeking Formulation of New Drug, Biopharma Co. Signs LOI

Research Report
  ()
Rakovina Therapeutics Inc. (RKV:TSX.V) is seeking a novel formulation or drug delivery modalities that could modify the pharmacokinetics of its anti-cancer drug kt3283 to be more tumor targeted, noted a Leede Financial Inc. report.
Tags: Biotechnology / Pharmaceuticals